drugset
drugset / Trial / NCT02820558

Neuropeptide Therapy of Recent Onset Type 1 Diabetes

NCT02820558 ↗

Phase 1 Unknown 12 enrolled Vanilloid Genetics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the delivery of substance P via the celiac artery in the treatment of recent onset type 1 diabetes.

Timeline

Start
2016-05
Primary completion
2022-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Substance P Small molecule 1 unknown Other
Subject Substance P Small molecule 5 unknown Other
Subject Substance P Small molecule 15 unknown Other
Subject Substance P Small molecule 45 unknown Other

Indications

type 1 diabetes mellitus